The release of those numbers comes just days after a watershed federal policy change: beginning July 1, 2026, eligible Medicare Part D beneficiaries can access GLP-1 medications approved for weight loss including Wegovy, oral Wegovy, Zepbound, and Foundayo for a flat $50 monthly copay through a new program called the Medicare GLP-1 Bridge
This design substantially reduces the amount of free silicone oil in contact with the drug product, thereby lowering the risk of protein aggregation and particle formation
With the support of our experienced Nurse Practitioner, Alexa, and the latest medical advancements, including the use of Semaglutide, this membership is your pathway to sustainable results
Whether you choose semaglutide with B12 or tirzepatide with B12, the B12 component serves the same purposes